NEW YORK, May 10, 2018 (GLOBE NEWSWIRE) -- Wolf Haldenstein Adler Freeman & Herz LLP announces that a class action lawsuit has
been filed in the United States District Court for the District of Utah on behalf of investors that purchased or otherwise acquired
securities of Myriad Genetics, Inc. (“Myriad” or the “Company”) (NASDAQ:MYGN) between August 13, 2014 through March 12,
2018, inclusive (the “Class Period”).
Investors who have incurred losses in shares of Myriad Genetics, Inc. are urged to
contact the firm immediately at classmember@whafh.com or (800) 575-0735 or (212) 545-4774. You may
obtain additional information concerning the action on our website, www.whafh.com.
If you have incurred losses in the shares of Myriad Genetics, Inc. and
would like to assist with the litigation process as a lead plaintiff, you may, no later than June 19,
2018, request that the Court appoint you lead plaintiff of the proposed class. Please contact Wolf Haldenstein to learn more about your rights as an investor in
Myriad Genetics, Inc.
The filed complaint filed alleges that Defendants made materially false and/or misleading statements and/or failed to disclose
that:
- Myriad was submitting false or otherwise improper claims for payment under Medicare and Medicaid for Myriad’s hereditary
cancer testing;
- the foregoing conduct would foreseeably subject Myriad to heightened regulatory scrutiny and/or enforcement action;
- Myriad’s revenues from its hereditary cancer testing were in part the product of improper conduct and unlikely to be
sustainable; and
- as a result, Myriad’s public statements were materially false and misleading at all relevant times.
On March 12, 2018, Myriad disclosed that it received a subpoena from the Department of Health and Human
Services (DHHS) in connection with an investigation into possible false Medicare and Medicaid payment claims. The subpoena
purportedly requested documents “relating primarily to the Company’s billing to government-funded healthcare programs for the
Company’s hereditary cancer testing.”
On this news, Myriad’s share price fell $4.01 per share, or 12.1%, to close at $29.01 per share on March 13,
2018.
Wolf Haldenstein Adler Freeman & Herz LLP has extensive experience in the prosecution of
securities class actions and derivative litigation in state and federal trial and appellate courts across the country. The
firm has attorneys in various practice areas; and offices in New York, Chicago and San Diego. The reputation and expertise of
this firm in shareholder and other class litigation has been repeatedly recognized by the courts, which have appointed it to major
positions in complex securities multi-district and consolidated litigation.
If you wish to discuss this action or have any questions regarding your rights and interests in this case,
please immediately contact Wolf Haldenstein by telephone at (800) 575-0735, via e-mail at classmember@whafh.com, or visit our website at www.whafh.com.
## Follow the firm and learn about newly filed cases on Twitter and Facebook. ##
Contact:
Wolf Haldenstein Adler Freeman & Herz LLP
Kevin Cooper, Esq.
Gregory Stone, Director of Case and Financial Analysis
Email: gstone@whafh.com, kcooper@whafh.com or classmember@whafh.com
Tel: (800) 575-0735 or (212) 545-4774
Attorney Advertising. Prior results do not guarantee or predict a similar outcome.
